Choose a language and wait for the translated text.
The Centreโs 30 per cent cap on trade margins of non-scheduled anti-cancer drugs is expected to improve pricing transparency and narrow price gaps between competing generics. However, the impact on patient affordability may vary, as patented therapies leave less room for trade margin corrections.
